ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
Genfit

Genfit (GNFT)

4.015
-0.01
( -0.25% )
更新日時: 18:42:26

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

主要統計と詳細

通貨
4.015
買値
4.005
売値
4.03
出来高
64,862
4.00 日の範囲 4.08
2.90 52 週間の範囲 5.86
時価総額
前日終値
4.025
始値
4.025
最終取引時間
18:42:23
財務取引量
-
VWAP
-
平均取引量 (3 か月)
332,826
発行済株式数
49,834,983
配当利回り
-
PER
-6.99
1 株当たり利益 (EPS)
-0.58
歳入
38.68M
純利益
-28.89M

Genfit について

セクター
Pharmaceutical Preparations
業界
Pharmaceutical Preparations
ウェブサイト
本社
Loos, Nord, Fra
設立
-
Genfit is listed in the Pharmaceutical Preparations sector of the ユーロネクスト with ticker GNFT. The last closing price for Genfit was 4.03 €. Over the last year, Genfit shares have traded in a share price range of 2.90 € to 5.86 €.

Genfit currently has 49,834,983 shares in issue. The market capitalisation of Genfit is 200.59 € million. Genfit has a price to earnings ratio (PE ratio) of -6.99.

GNFT 最新ニュース

GENFIT fait un point d’actualité sur ses activités à l’occasion de sa participation prochaine à l’AASLD Liver Meeting® 2024

GENFIT fait un point d’actualité sur ses activités à l’occasion de sa participation prochaine à l’AASLD Liver Meeting® 2024 Programme PBC (sous licence Ipsen) : Ipsen présentera de nouvelles...

GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024

GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024 PBC program (licensed to Ipsen): Ipsen to present new data on elafibranor at The Liver Meeting® 2024Launch...

GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024

PBC program (licensed to Ipsen): Ipsen to present new data on elafibranor at The Liver Meeting® 2024Launch of Iqirvo® (elafibranor)1 on track with expectations; encouraging feedback from...

GENFIT : Information financière du troisième trimestre 2024

GENFIT : Information financière du troisième trimestre 2024 Trésorerie et équivalents de trésorerie s’élevant à 96,0 millions d’euros au 30 septembre 202459,7 millions d’euros de revenus des neuf...

GENFIT Reports Third Quarter 2024 Financial Information

GENFIT Reports Third Quarter 2024 Financial Information Cash and cash equivalents totaled €96.0 million as of September 30, 2024€59.7 million in revenues for the nine months ended September 30...

GENFIT Reports Third Quarter 2024 Financial Information

Cash and cash equivalents totaled €96.0 million as of September 30, 2024€59.7 million in revenues for the nine months ended September 30, 2024, including the €48.7 million milestone invoiced in...

GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval

GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval Lille (France), Cambridge...

GENFIT : Iqirvo® d’Ipsen (elafibranor) reçoit l’approbation UE en tant que traitement first-in-class de la Cholangite Biliaire Primitive consécutivement à l’approbation accélérée de la FDA américaine

GENFIT : Iqirvo® d’Ipsen (elafibranor) reçoit l’approbation UE en tant que traitement first-in-class de la Cholangite Biliaire Primitive consécutivement à l’approbation accélérée de la FDA...

GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 23, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to...

GENFIT : Résultats financiers du premier semestre 2024 et point sur les activités de la Société

GENFIT : Résultats financiers du premier semestre 2024 et point sur les activités de la Société Trésorerie et équivalents de trésorerie s’élevant à 61,6 millions d’euros au 30 juin 2024 n’incluant...

期間 †前日比前日比 %始値高値安値平均出来高VWAP
1-0.875-17.89366053174.894.95543890694.21865211DE
4-1.115-21.73489278755.135.6343168594.84595068DE
120.2055.380577427823.815.863.6253328264.88488944DE
260.1955.104712041883.825.863.473373254.60435271DE
520.86527.46031746033.155.862.92656144.1910778DE
1560.83726.33731906863.1785.862.7462139263.93819091DE
260-9.885-71.115107913713.920.962.7463118015.60966838DE

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
ALMASMastrad
0.0136 €
(58.14%)
976.27k
BIDSGascogne DS
0.0028 €
(55.56%)
40.05k
SOISOITEC
75.20 €
(18.43%)
193.43k
HYLHyloris Pharmaceuticals SA
5.88 €
(13.51%)
36.48k
ATODSAtos SE
0.0046 €
(12.20%)
12.01M
EBUSEbusco Holding NV
0.918 €
(-25.12%)
1.47M
VACBSPierre & Vacances
0.048 €
(-14.29%)
427
EMGDSEuromedis DS
0.0088 €
(-12.00%)
2.65k
ALVETTheraVet SA
0.0804 €
(-10.67%)
28.93k
ALAIRGroupe Airwell
1.43 €
(-9.49%)
1.57k
ATODSAtos SE
0.0046 €
(12.20%)
12.01M
ALVERVergnet
0.005 €
(4.17%)
7.64M
ALTDTonner Drones
0.0102 €
(10.87%)
6.92M
BCPBanco Comercial Portugues SA
0.4354 €
(-1.00%)
6.87M
ATOAtos SE
0.1767 €
(-8.21%)
2.8M

最近閲覧した銘柄

Delayed Upgrade Clock